Cary Twyman

Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial

Alasdair Coles, Cary Twyman, Douglas L. Arnold et al. · The Lancet · 2012 · 1.2K citations · Full text

Immunology, Clinical Trials, Neurological Progress +4

Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND): a phase 3, randomised, double-blind, placebo-controlled trial with an open-label extension

Raju Kapoor, Pei‐Ran Ho, Nolan Campbell et al. · The Lancet Neurology · 2018 · 327 citations · Full text

Disease Progression, Neurological Disorder, Immunology +8

B cell depletion with ublituximab reshapes the T cell profile in multiple sclerosis patients

Amy E. Lovett‐Racke, Matthew Gormley, Yue Liu et al. · Journal of Neuroimmunology · 2019 · 47 citations · Full text

Adaptive Immune System, T-regulatory Cell, Immunology +17

Acidities and homolytic bond dissociation energies (BDEs) of benzyl-type carbon-hydrogen bonds in sterically congested substrates

F. G. Bordwell, Jin Cheng, A. V. Satish et al. · The Journal of Organic Chemistry · 1992 · 38 citations

Engineering, Altmetric Attention Score, Organic Chemistry +16

Durable Efficacy of Alemtuzumab in Relapsing-Remitting Multiple Sclerosis Patients Who Participated in the CARE-MS Studies: Three Year Follow-Up (S41.001)

Edward Fox, Douglas L. Arnold, Jeffrey Cohen et al. · Neurology · 2013 · 13 citations